knowledge -WSS

knowledge

author：Wikipedia 2025-09-30 18:54:01 - browse：62897

Vials and packaging for Leqembi, a new Alzheimer's medication approved in the U.S., but not yet in Europe. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

LONDON — Starting Sunday, Alzheimer’s specialists will gather for a major conference in Amsterdam, convening at a time when the field, depending on which expert you ask, has some rare momentum behind it, with new therapies starting to show benefits for patients.

But despite the hard-won victories, the arrival of the new therapies presents a new set of challenges in Europe as countries plan for their possible rollouts, scientists and doctors told STAT.

Health systems will have to adapt to diagnose people earlier and monitor them for side effects associated with the treatments. If their medicines win European approval, companies will have to strike reimbursement deals in all member states, a process that often leaves some countries waiting years for new drugs to become available. The hurdles mean the therapies will likely be offered only at certain centers initially, constraining how many patients have access to them, doctors from across Europe said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Histogen: Failed biotech offers rare public look inside

WSS

'Make People Better': The CRISPR babies story you probably don't know

A rare thyroid diagnosis led to unexpected, all

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Medicaid rebukes states for mistakenly disenrolling children

Colorectal cancer study finds potential in overlooked immune cell

Snackable artificial intelligence, expert AI, and the pharma industry

focus

knowledge

hotspot

How to save PrEP access — and even expand it

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Liquid biopsy for lung cancer is launched by Delfi

Drug repurposing or repositioning? The language matters

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Jerome Adams on the need for new antivirals for Covid

How to protect patients from sexual assault

What does generative AI mean for health care? We asked experts

Liquid biopsy for lung cancer is launched by Delfi

hotspot

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Why Charlie Gard's case is so disturbing to Americans

A new House health package & hospitals’ new site

Snackable artificial intelligence, expert AI, and the pharma industry

Stroke deaths set to near 10 million globally by 2050

The 10 drugs up first for Medicare price negotiation

entertainment

focus

entertainment

knowledge